title: Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression.
abstract: The presentation of endogenously synthesized peptides in association with HLA class I molecules allows the activation of CD8(+) lymphocytes. Tumor cells often fail to present antigenic peptides resulting in the immune escape of metastasizing cells. The aim of this study was to elucidate possible molecular mechanisms leading to reduced antigen presentation in melanoma. Melanoma cell short-time cultures were genotypically and phenotypically HLA-typed by sequence-specific primer polymerase chain reaction and complement-mediated microlymphocytotoxicity assays, respectively. Flow cytometric analysis of HLA-A2 and HLA-A3 allospecificities were performed to confirm typing results. Transcriptional levels of classical HLA-A, HLA-B genes and nonclassical HLA-G genes were detected using quantitative real-time reverse transcriptase polymerase chain reaction (LightCycler). We found loss or downregulation of HLA proteins in 18% (for HLA-A) and 53% (for HLA-B) of all tested metastases. Genomic analysis, however, revealed the presence of the corresponding HLA class I gene in six out of seven cases. On the level of gene transcription we observed a differential regulation of HLA-A, HLA-B, and HLA-G mRNA expression. There was no correlation between classical and nonclassical HLA gene transcription, but the transcriptional levels of classical HLA corresponded to the protein expression levels. Furthermore, an overall reduced amount of HLA class I gene transcription was observed in melanoma metastases during disease progression in three individuals. We postulate that there is a transcriptional regulation of HLA class I gene expression in melanoma cells. These data suggest that treatment approaches aimed at activating specific cytotoxic T lymphocytes are most successful in early disease.
authors.affiliation: Department of Dermatology, University Hospital of Zurich, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Willers
authors.forename: M
authors.initials: M
authors.lastname: Urosevic
authors.forename: E
authors.initials: E
authors.lastname: Laine
authors.forename: R
authors.initials: R
authors.lastname: Geertsen
authors.forename: T
authors.initials: T
authors.lastname: Kündig
authors.forename: G
authors.initials: G
authors.lastname: Burg
authors.forename: R
authors.initials: R
authors.lastname: Dummer
mesh_terms: D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology*; D005838:Genotype; D006680:HLA Antigens / Q000235:genetics*; D015234:HLA-A Antigens / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D008545:Melanoma / Q000235:genetics* / Q000556:secondary; D010641:Phenotype; D012878:Skin Neoplasms / Q000235:genetics* / Q000556:secondary; D014158:Transcription, Genetic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I